Hormone replacement therapy and venous thromboembolism

Climacteric

Volumn 2, Issue 3, 1999, Pages 224-231

  Greer, I A ^a   Walker, I D ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ESTROGEN THERAPY; FEMALE; GENETICS; HEMOSTASIS; HUMAN; MIDDLE AGED; REVIEW; RISK FACTOR; SURGERY; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEMOSTASIS; HUMANS; MIDDLE AGED; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0033200477     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.3109/13697139909038066     Document Type: Article

References (29)

1. Carter C. The pill and thrombosis: epidemiological considerations. Baillière's Clin Obstet Gynaecol 1997;11:565-85
2. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M and MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case control study. Br Med J 1996;312:83-8
3. Carter CJ. Pathogenesis of thrombosis. In Greer IA, Turpie AG, Forbes CD, eds. Haemostasis and Thrombosis in Obstetrics and Gynaecology. London: Chapman & Hall, 1992:229-55
4. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of admission for idiopathic venous thromboembolism among users of post-menopausal oestrogens. Lancet 1996;348:981-3
5. Daly E, Vessey MP, Hawkins MM, Carton JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80
6. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-7
7. Gutthann SP, Garcia Rodriguez LA, Castallsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997;314: 796-800
8. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1994;74:77-81
9. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775-84
10. Tait RC, Walker ID, Islam SI, et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993;84: 467-80
11. Tait RC, Walker ID, Islam SI, et al. Protein C activity in healthy volunteers: influence of age, sex, smoking and oral contraceptives. Thromb Haemostas 1993;70:281-5
12. Lindoff C, Peterson F, Lecander I, Martinsson G, Astedt B. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas 1996;24:43-50
13. Anonymous. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: one year double-blind placebo controlled study. The Writing Group for the Estradiol Clotting Factors Study. Thromb Haemost 1996; 75:476-80
14. Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone replacement therapy on hemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997;134:764-71
15. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336:683-90
16. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing prostagen components. Lancet 1995;346: 1589-93
17. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. PEPI (The Postmenopausal Estrogen/Progestin Interventions Trial) Writing Group. J Am Med Assoc 1995;273:199-208
18. Walker ID. Congenital thrombophilia. Baillières Clin Obstet Gynaecol 1997;11:431-45
19. Dahlback B, Hillarp A, Rosen S, Zoller B. Resistance to activated protein C, the FV:Q506 allele and venous thrombosis. Ann Hematol 1996;72: 166-76
20. Zoller B, Holm J, Dahlback B. Resistance to activated protein C due to a factor V gene mutation: the most common inherited risk factor of thrombosis. Trends Cardiovasc Med 1996;6: 45-53
21. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: A new mutation (Arg306→ Thr) associated with resistance to activated protein C. Blood 1998;91:1140-4
22. Poort SR, Rosendall FR, Reitsma PH, Bertina RM. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703
23. Van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in post-menopausal women. Eur J Clin Invest 1994;24:733-6
24. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-13
25. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V association with resistance to activated protein C. Nature 1994;369:64-7
26. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992;305:567-74
27. Whitehead M, Godfree V. Venous thromboembolism and hormone replacement therapy. Baillières Clin Obstet Gynaecol 1997;11:587-99
28. Greer IA. Practical strategies for hormone replacement therapy and risk of venous thromboembolism. Br J Obstet Gynaecol 1998;105: 376-9
29. Greer IA. Epidemiology risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology. Baillières Clin Obstet Gynaecol 1997;11:403-30